AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$NMRA

Aurora Daljit Singh sold $135K of NMRA

Aurora Daljit Singh (See Remarks) sold 88,294 shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.53 ($1.51–$1.59, $0.14M total) across 2 trades over 2026-08-20 to 2026-08-21.

Original reporting
SEC EDGAR · Aurora Daljit Singh
Published Aug 21, 2026, 11:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NMRA
Bearish
medium confidence
Mentioned
$NMRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NMRABearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short-term traders.

02

Market read

New insider sale information may influence short-term trading decisions on NMRA.

03

What to watch

Potential upcoming clinical data releases could offset the sale impact.

Relevance 4/10Novelty 4/10Timing: filing date 2026-08-21

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$NMRABearishMedium confidence
Context

Officer Aurora Daljit Singh sold 88,294 shares for $135,367, reducing his stake to 48,750 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

Sale size is modest relative to market cap, but insider sales often attract short-term selling.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Neumora Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker NMRA.

  • Officer
    Aurora Daljit Singh

    Company officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NMRA insider trading history →

Related articles

AUG 14
$NMRAMed

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics (Nasdaq: NMRA) reported Q2 2026 results and a pipeline update. It said NMRA-215 IND submission is planned for Q4 2026 with Phase 1 initiation by year end. NMRA-511 AD agitation data are expected in Q4 2026, and NMRA-898 schizophrenia Phase 1 data in 2H 2026. Cash was $116.8M, funding operations into Q3 2027; Q2 net loss was $43.1M.

finanznachrichten.de4 min
AUG 14
$NMRAMed

Neumora Therapeutics, Inc. (NMRA): Results of Operations and Financial Condition

Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzhe

SEC EDGAR 8-K6 min
JUN 19
$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

rttnews.com6 min
JUN 16
$NMRAMedAI 8/10

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Levi & Korsinsky said it has opened an investigation into Neumora Therapeutics’ officers and directors after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction. The article notes the stock fell nearly 50% and cites prior company comments during earnings and in January 2026.

prnewswire.com3 min